Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real‐World Data From the UK : A Nested Case–Control and Case‐Crossover Study
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Donya Moslemzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlan…. Hauptthemen laut MEDLINE: Sulfones, Lactones, Cardiovascular Diseases, Cyclooxygenase 2 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Traditional pharmacovigilance systems have limitations in detecting common adverse drug reactions. We investigated whether real‐world data (RWD) could have detected rofecoxib's cardiovascular adverse effects earlier using nested case–control (NCC) and case‐crossover (CCO) designs.
Methods
We included adult rofecoxib users from the UK CPRD GOLD (1999–2004). In NCC design, cases of a first major adverse cardiovascular event (MACE) were matched with four controls on age, sex, practice and calendar time. Rofecoxib exposure was categorised as current (≤ 3 months), recent (3–6), or past use (> 6) in NCC, and assessed at the start of each 3‐month interval in CCO design. Exposure odds in CCO were compared between a 3‐month risk with four reference windows. Conditional logistic regression models estimated adjusted intensity ratio (aIR). To identify the shortest time necessary to detect the association, analyses were conducted in 1‐, 2‐, 3‐, 4‐ and 5‐years after the drug's market uptake.
Results
Three thousand two hundred and eighteen cases were matched to 10 745 controls (mean age 73.8 years, 66% female). In NCC, current rofecoxib use (42% of cases) was associated with an 18% higher risk of MACE (aIR 1.18, 95% CI 1.08–1.29) versus past use. The CCO (3210 risk and 12 737 reference windows) showed an 83% increased risk of MACE (aIR 1.83, 95% CI 1.53–2.18). First signal emerged after 2 years with CCO (aIR 3.94, 95% CI 1.88–8.25), and after 3 years with NCC design (aIR 1.46, 95% CI 1.18–1.81).
Conclusion
Using RWD, cardiovascular adverse effects of rofecoxib could have been detected within 2 years of the market entry in the UK, well before traditional pharmacovigilance methods. This supports incorporating RWD analysis into routine drug safety monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
- Research Group Innovations of Pharmaceutical Care, Utrecht University of Applied Sciences, Utrecht, the Netherlands.
Zitieren
APA
Moslemzadeh, D., Souverein, P. C., Belitser, S. V., Heerdink, E. R., Klungel, O. H., & Abtahi, S. (2026). Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real‐World Data From the UK : A Nested Case–Control and Case‐Crossover Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70343
Vancouver
Moslemzadeh D, Souverein PC, Belitser SV, Heerdink ER, Klungel OH, Abtahi S. Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real‐World Data From the UK : A Nested Case–Control and Case‐Crossover Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70343
BibTeX
@article{Moslemzadeh2026,
author = {Moslemzadeh, Donya and Souverein, Patrick C and Belitser, Svetlana V and Heerdink, Eibert R and Klungel, Olaf H and Abtahi, Shahab},
title = {Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real‐World Data From the UK : A Nested Case–Control and Case‐Crossover Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70343}
}
EUVIMED